Immunotherapy (Pembrolizumab)(Merck)은 Locally Advanced Esophageal Squamous Cel 표적 항체로, Melanoma (Skin Cancer); Melanoma Stage IIIB-IV 영역에서 개발·상용화 중입니다. 작용기전: targeting via chimeric antigen receptor (CAR) against a novel ES target interleukin-1 receptor. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 38% (ClinicalTrials.gov NCT02444741). PK: t½ 3 h. 차별점: novel ES target interleukin-1 receptor accessory protein (IL1RAP), circumventing transforming growth factor beta (TGFβ).
Locally Advanced Esophageal Squamous Cel
Melanoma (Skin Cancer); Melanoma Stage IIIB-IV
Recruiting
CAR-T development and immunotherapy target identification
Vedotin ± Pembrolizumab
lipid nanoparticle (LNP) therapeutics
humanized monoclonal antibody (mAb) targeting lymphocyte activation gene-3 (LAG-3)
novel ES target interleukin-1 receptor accessory protein (IL1RAP), circumventing transforming growth factor beta (TGFβ)
targeting via chimeric antigen receptor (CAR) against a novel ES target interleukin-1 receptor
cytokine release syndrome, immune effector cell-associated neurotoxicity, and tumor inflammation-associated neurotox
apoptosis of ES cells, upregulated expression of ligands to NK inhibitory receptors on ES cells, and enhanced mouse macrophage mi
biomarkers, enhanced trial matching, and scalable cohort identification
resistance to NK cells by a combinatorial immunotherapy approach simultaneously enabling NK tumor-specific-targeting via chimeric ant
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Immunotherapy (Pembrolizumab)(Merck)은 Locally Advanced Esophageal Squamous Cel 표적 항체로, Melanoma (Skin Cancer); Melanoma Stage IIIB-IV 영역에서 개발·상용화 중입니다. 작용기전: targeting via chimeric antigen receptor (CAR) against a novel ES target interleukin-1 receptor. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 38% (ClinicalTrials.gov NCT02444741). PK: t½ 3 h. 차별점: novel ES target interleukin-1 receptor accessory protein (IL1RAP), circumventing transforming growth factor beta (TGFβ).
Locally Advanced Esophageal Squamous Cel
Melanoma (Skin Cancer); Melanoma Stage IIIB-IV
Recruiting
CAR-T development and immunotherapy target identification
Vedotin ± Pembrolizumab
lipid nanoparticle (LNP) therapeutics
humanized monoclonal antibody (mAb) targeting lymphocyte activation gene-3 (LAG-3)
novel ES target interleukin-1 receptor accessory protein (IL1RAP), circumventing transforming growth factor beta (TGFβ)
targeting via chimeric antigen receptor (CAR) against a novel ES target interleukin-1 receptor
cytokine release syndrome, immune effector cell-associated neurotoxicity, and tumor inflammation-associated neurotox
apoptosis of ES cells, upregulated expression of ligands to NK inhibitory receptors on ES cells, and enhanced mouse macrophage mi
biomarkers, enhanced trial matching, and scalable cohort identification
resistance to NK cells by a combinatorial immunotherapy approach simultaneously enabling NK tumor-specific-targeting via chimeric ant
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.